首页> 外文期刊>Current pain and headache reports. >Drug Combinations in the Treatment of Neuropathic Pain
【24h】

Drug Combinations in the Treatment of Neuropathic Pain

机译:药物组合治疗神经性疼痛

获取原文
获取原文并翻译 | 示例
           

摘要

Pharmacotherapy, the main treatment option for neuropathic pain, remains a major clinical challenge. The most commonly studied drug classes in the context of neuropathic pain-antidepressants, anticonvulsants, and opioids-have only limited efficacy and frequent dose-limiting adverse effects. Yet, most guidelines recommend monotherapy as the first line of neuropathic pain treatment. Recent understanding of neuropathic pain pathophysiology suggests that multiple mechanisms, both at the peripheral and the central nervous system levels, underlie neuropathic pain, pointing to the possibility that targeting multiple mechanisms simultaneously can improve treatment outcome. A few clinical trials using various drug combinations for neuropathic pain have already been published but yielded inconsistent results, partially due to methodological problems associated with the conduction of such trials. Nonetheless, combination therapy remains an intriguing treatment option for neuropathic pain, awaiting future high-quality validating trials.
机译:药物疗法是神经性疼痛的主要治疗选择,仍然是主要的临床挑战。在神经性止痛药,抗惊厥药和阿片类药物中,最常研究的药物类别仅具有有限的疗效和常见的剂量限制性副作用。然而,大多数指南建议将单一疗法作为神经性疼痛治疗的第一线。对神经性疼痛病理生理学的最新认识表明,神经性疼痛是周围和中枢神经系统水平的多种机制的基础,这表明同时靶向多种机制可以改善治疗效果的可能性。已经发表了一些使用各种药物组合治疗神经性疼痛的临床试验,但结果不一致,部分原因是与进行这类试验有关的方法学问题。尽管如此,联合治疗仍然是神经性疼痛的一种有趣的治疗选择,等待着未来的高质量验证试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号